1 Min Read
Dec 18 (Reuters) - Astrazeneca Plc:
* FDA ACCEPTS TAGRISSO SUBMISSION FOR 1ST-LINE NSCLC
* US FDA ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.